Michael Rothenberg: A next generation BRAF Inhibitor shows promise in treatment refractory cancer patients

Michael Rothenberg, Chief Medical Officer at Insitro, shared on LinkedIn:

“The Pfizer, Pfizer Boulder Research Unit, and academic collaborators’ clinical and translational work on PF-07799933 (ARRY-440) is out in the September issue of Cancer Discovery. A next-generation, brain-penetrant, pan-mutant BRAF-selective inhibitor, together with innovative and accelerated phase 1 clinical development with demonstrated efficacy in treatment-refractory cancer patients.”

A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation 

Authors: Rona Yaeger, Meredith A. McKean, Rizwan Haq, J. Thaddeus Beck, Matthew H. Taylor, Jonathan E. Cohen, Daniel W. Bowles, Shirish M. Gadgeel, Catalin Mihalcioiu, Kyriakos P. Papadopoulos, Eli L. Diamond, Keren B. Sturtz, Gang Feng, Stefanie K. Drescher, Micaela B. Reddy, Bhaswati Sengupta, Arnab K. Maity, Suzy A. Brown, Anurag Singh, Eric N. Brown, Brian R. Baer, Jim Wong, Tung-Chung Mou, Wen-I Wu, Dean R. Kahn, Sunyana Gadal, Neal Rosen, John J. Gaudino, Patrice A. Lee, Dylan P. Hartley, S. Michael Rothenberg

Source: Michael Rothenberg/LinkedIn